Clean Yield Group Cuts Position in Novo Nordisk A/S (NYSE:NVO)

Clean Yield Group trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.4% during the first quarter, HoldingsChannel reports. The institutional investor owned 33,076 shares of the company’s stock after selling 800 shares during the quarter. Clean Yield Group’s holdings in Novo Nordisk A/S were worth $2,297,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Center for Financial Planning Inc. lifted its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL lifted its stake in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $29,000. Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $33,000. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $39,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $74.70 on Friday. The firm has a market cap of $335.22 billion, a P/E ratio of 22.71, a P/E/G ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The firm has a fifty day moving average of $65.87 and a two-hundred day moving average of $80.54. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Finally, BMO Capital Markets restated a “market perform” rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $128.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.